1. Home
  2. BTBD vs APVO Comparison

BTBD vs APVO Comparison

Compare BTBD & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BT Brands Inc.

BTBD

BT Brands Inc.

HOLD

Current Price

$2.09

Market Cap

10.0M

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

N/A

Current Price

$5.00

Market Cap

8.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTBD
APVO
Founded
1987
2016
Country
United States
United States
Employees
188
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BTBD
APVO
Price
$2.09
$5.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
801.5K
27.6K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.25
52 Week High
$5.59
$13.11

Technical Indicators

Market Signals
Indicator
BTBD
APVO
Relative Strength Index (RSI) 57.85 50.52
Support Level $1.58 $3.88
Resistance Level $2.14 $5.69
Average True Range (ATR) 0.23 0.34
MACD -0.02 0.06
Stochastic Oscillator 56.67 53.53

Price Performance

Historical Comparison
BTBD
APVO

About BTBD BT Brands Inc.

BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: